Opendata, web and dolomites

MOXO-Mobile Phase-1 SIGNED

MOXO-Mobile: the first Attention Deficit Hyperactive Disorder (ADHD) screening mobile application, using Eye Tracking and Continuous Performance Test components to give the first evidence of attention

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "MOXO-Mobile Phase-1" data sheet

The following table provides information about the project.

Coordinator
NEURO TECHNOLOGY SOLUTIONS LTD 

Organization address
address: HAPLADA 3
city: OR YEHUDA
postcode: 6021803
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-08-01   to  2020-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    NEURO TECHNOLOGY SOLUTIONS LTD IL (OR YEHUDA) coordinator 50˙000.00

Map

 Project objective

Undiagnosed ADHD leads to learning and social difficulties, school drop-out, unemployment, criminality, and even premature death.

Early diagnosis can dramatically improve the quality of life of at least 26 million individuals in the EU, prevent incarceration and recidivism, and save lives.

MOXO-Mobile is the first ADHD screening mobile application, combining a Continuous Performance Test (CPT) and Eye Tracking (ET) to give an accurate and simple evaluation of the evidence of attentional difficulties. Using this application, every smartphone user could assess his/her attention level and profile and receive further guidance, in case of need, for further diagnosis.

The application will be downloaded for free with pay-per-use strategy as the user will purchase tests as he wishes for himself and his family.

MOXO-Mobile will create a new market (ADHD screening), with max market potential of €2.8B, and a projected ROI of 6.1 in 3 years for MOXO-Mobile.

SMEi Phase 1 will enable Neurotech-Solutions to conduct a wide feasibility study, establish an elaborated business plan, risk assessment, and a sustainability estimation of the product.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MOXO-MOBILE PHASE-1" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MOXO-MOBILE PHASE-1" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

RDNA (2019)

Empowering New Venture Growth - RDNA

Read More  

MEDIVAC (2019)

Machine learning software to design personalized neoantigen vaccines tailored to specific vaccine delivery systems

Read More  

Manuback (2019)

MANUBACK, the smart garment for operator protection in the field of Manual Handling of Goods

Read More